The CJC-1295 / Ipamorelin combination is the most-studied GH peptide stack in research. Here is a detailed breakdown of how each component works and why they are used together.
Growth hormone (GH) secretion is regulated through two primary pathways: the growth hormone releasing hormone (GHRH) axis and the ghrelin/GHS-R1a (growth hormone secretagogue receptor) axis. The CJC-1295 + Ipamorelin stack is remarkable because it activates both pathways simultaneously — something that naturally occurring GH pulses do not do with the same magnitude.
CJC-1295 is a synthetic analogue of growth hormone releasing hormone (GHRH) — the hypothalamic signal that stimulates pituitary somatotrophs to produce and secrete GH. The "without DAC" formulation (as used in the Corevanta blend) refers to the absence of the Drug Affinity Complex modification, which gives it a shorter half-life that more closely mirrors natural pulsatile GHRH signaling.
CJC-1295 binds to GHRH receptors on pituitary cells and triggers a downstream signaling cascade involving adenylyl cyclase activation, cAMP production, and ultimately GH gene transcription and secretion. Research in animal models has shown significant increases in baseline GH levels following GHRH analogue administration.
Ipamorelin is a selective pentapeptide GH secretagogue — it mimics ghrelin and acts through the GHS-R1a receptor, a completely separate pathway from GHRH. What distinguishes Ipamorelin from other GHRPs (like GHRP-6 or hexarelin) is its exceptional selectivity: it stimulates GH release without meaningfully elevating cortisol, prolactin, aldosterone, or ACTH. This cleaner profile makes it highly valuable for research designs where hormonal co-stimulation would confound results.
Ipamorelin alone produces dose-dependent increases in pulsatile GH release. Combined with CJC-1295, the two compounds synergize through their different receptor systems to produce GH pulses significantly larger than either compound alone — an interaction well-supported in preclinical data.
When both compounds are administered together: - CJC-1295 loads the pituitary somatotrophs (primes them to fire) - Ipamorelin triggers the release pulse through the ghrelin receptor
The resulting GH output is amplified compared to either compound alone. Researchers studying GH biology, body composition, bone density, and recovery processes frequently use this combination for its predictable, pulsatile response pattern.
The key downstream mediator of GH's effects is insulin-like growth factor-1 (IGF-1), produced primarily in the liver in response to GH signaling. IGF-1 drives anabolic processes across multiple tissues: muscle protein synthesis, bone formation, fat oxidation, and connective tissue repair. Research protocols using CJC-1295 / Ipamorelin often measure both acute GH peaks and longer-term IGF-1 elevation as the primary endpoints.
Both CJC-1295 and Ipamorelin have well-established preclinical safety profiles. The combination does not appear to suppress endogenous GH production — it works with the body's existing pulsatile rhythm rather than replacing it, which differentiates it from exogenous GH administration in study design terms.
The Corevanta CJC / Ipamorelin blend combines both compounds in a single lyophilized vial, verified at ≥99% purity by HPLC and LC-MS.
*All products sold by Corevanta are for research purposes only and are not intended for human use.*
Research compounds discussed in this article
All compounds discussed in this article are sold by Corevanta for laboratory research purposes only. They are not approved drugs, not dietary supplements, and are not intended for human consumption or therapeutic use. Always comply with applicable local regulations.